Skip to main content
SpringerLink
Log in

Antisense Efficacy

Site-Restricted In Vivo and Ex Vivo Models

  • Protocol
Antisense Therapeutics

Part of the book series: Methods in Molecular Medicine ((MIMM,volume 1))

Abstract

In the laboratory, antisense oligodeoxynucleotides (ODN) have repeatedly demonstrated efficacy in modulating the expression of various genes, thus providing important insights into their roles in tumorigenesis or normal growth and development (1–3). Although attention has been focused recently on the development of antisense ODN as therapeutics for a variety of diseases, including cancer (4), systemic application of ODN to treat tumors other than those of the hematopoietic system presents several problems, not least of which is the ability of systemically administered antisense to reach distant tumor sites. This is particularly true when considering tumors of the central nervous system (CNS), such as glioblastomas and HIV-associated B-cell lymphomas. In this case, the blood-brain barrrer poses an additional obstacle to successful delivery of anionic ODN. On the other hand, the intractability of CNS tumors to standard chemotherapy makes them interesting candidates for antisense intervention. The first model system we will discuss mvolves direct mfusron of ODN into the CNS for the purpose of continuous perfusion of tumor cells.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Protocol
USD 49.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 109.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Cohen, J S (1991) Chemically modified oligodeoxynucleotide analogs as regulators of viral and cellular gene expression, in Gene Regulation. Biology of Antisense RNA and DNA (Erickson, R. P. and Izant, J. G., eds.), Raven, New York, pp. 247–260.

    Google Scholar 

  2. Goodchtld, J. (1989) Inhibition of gene expression by oligonucleotides, in Oligodeoxynucleotides Antisense Inhibitors of Gene Expression (Cohen, J. S, ed), Macmillan, London, pp 53–77.

    Google Scholar 

  3. Neckers, L., Whitesell, L, Rosolen, A., and Geselowitz, D. A. (1992) Antisense inhibition of oncogene expression. CRC Crit. Rev Oncogenesis 3, 175–231.

    CAS  Google Scholar 

  4. Zamecnik, P C (1991) Oligonucleotide based hybridization as a modulator of genetic message readout, in Prospects for Antisense Nucleic Acid Therapy of Cancer and AIDS (Wickstrom, E., ed.), Wiley-Liss, New York, pp. 1–6.

    Google Scholar 

  5. Neckers, L.M. (1993) Cellular Internalization of oligodeoxynucleotides, in Antisense Research and Appllcations (Crooke, S. T. and Lebleu, B, eds.), CRC, Boca Raton, FL, pp. 451–460.

    Google Scholar 

  6. Whitesell, L., Rosolen, A., and Neckers, L M (1991) In vivo modulation of N-myc expression by continuous perfusion with an antisense oligonucleotide Antisense Res Dev 1, 343–350.

    PubMed  CAS  Google Scholar 

  7. Srmons, M., Edelman, E. R., DeKeyser, J.-L., Langer, R, and Rosenberg, R. D (1992) Antisense c-myb oligonucleotides inhibit intimal arterial smooth muscle cell accumulation in vivo Nature 359, 67–70.

    Article  Google Scholar 

  8. Whttesell, L, Geselowitz, D., Chavany, C., Fahmy, B., Walbndge, S, Alger, J.R., and Neckers, L M (1993) Stability, clearance, and disposition of intraventricularly administered oligodeoxynucleotides implications for therapeutic application within the central nervous system. Proc. Natl Acad SCi USA 90, 4665–4669

    Article  Google Scholar 

  9. Bass, N and Lundborg, P (1973) Postnatal development of bulk flow in the cerebrospinal fluid system of the albino rat clearance of carboxyl-(14C)inulin after intrathecal infusion Brain Res 52, 323–332.

    Article  PubMed  CAS  Google Scholar 

  10. Agrawal, S, Temsamam, J, and Tang, Y T. (1991) Pharmacokmettcs, bio-distribution, and stability of oligodeoxynucleotide phosphorothioates in mice. Proc Natl Acad Set USA 88, 7595–7599.

    Article  CAS  Google Scholar 

  11. Poplack, D. G and Riccardi, R (1987) The role of pharmacology in pediatric oncology, in The Role of Pharmacology in Pediatrie Oncology (Poplack, D G., Massimo, L, and Cornagha-Ferraris, P., eds.), Martinus Nijhoff, Boston, pp 137–156.

    Google Scholar 

  12. Blaney, S. M., Balis, F.M., and Poplack, D. G. (1991) Pharmacologic approaches to the treatment of meningeal malignancy. Oncology 5, 107–116.

    PubMed  CAS  Google Scholar 

  13. Machado, M, Salcman, M, Kaplan, R.S, and Montgomery, E (1985) Expanded role of the cerebrospinal fluid reservoir in neurooncology: indications, causes of revision, and complications. Neurosurgery 17, 600–603

    Article  PubMed  CAS  Google Scholar 

  14. Sundaresan, N and Suite, N. D. A (1989) Optimal use of the omaya reservoir in clinical oncology. Oncology 3, 15–22

    PubMed  CAS  Google Scholar 

  15. Urch, C, George, A, Stevenson, G, Bolognesi, A, Stirpe, F, Weller, R, and Glennie, M (1991) Intra-thecal treatment of leptomeningeal lymphoma with immunotoxin Int J Cancer 47, 909–915

    Article  PubMed  CAS  Google Scholar 

  16. Moseley, R P., Papanastassiou, V, Zalutsky, M R, Ashpole, R. D., Evans, S., Bigner, D.D, and Kemshead, J.T. (1992) Immunoreactivny, pharmacokinetics and bone marrow dosimetry of intrathecal radioimmunoconjugates. Int J Cancer 52, 38–43

    Article  PubMed  CAS  Google Scholar 

  17. List, J., Moser, R. P., Steuer, M., Loudon, W. G, Blacklock, J. B, and Grimm, E. A(1992) Cytokine responses to intraventricular injection of interleukin 2 into patients with leptomeningeal carcinomatosis rapid induction of tumor necrosts factor alpha, interleukin 1 beta, interleukin 6, gamma-Interferon, and soluble mterleukin 2 receptor (M, 55,000 protein). Cancer Res 52, 1123–1128

    PubMed  CAS  Google Scholar 

  18. Pluda, J. M., Yarchoan, R, Jaffe, E. S, Feurstem, I. M., Solomon, D., Steinberg, S M, Wyvill, M., Raubnschek, A, Katz, D, and Broder, S. (1990) Development of non-Hodgkin lymphoma in a cohort of patients with severe human immunodeficiency virus (HIV) infection on longterm antiretroviral therapy Ann Intern Med 113, 276–282.

    PubMed  CAS  Google Scholar 

  19. McCarthy, M M., Brooks, P. J., Pfaus, J. G., Brown, H. E., Flanagan, L. M., Schwartz-Giblin, S., and Pfaff, D W (1993) Antisense oligodeoxynucleotides in behavioral neuroscience. Neuroprotocols 2, 64–66.

    Article  Google Scholar 

  20. La Rocca, R.V, Rosenblum, M, Westermark, B., and Israel, M. A (1989) Patterns of protooncogene expression in human glioma cell lines J Neurosci Res 24, 97–106.

    Article  CAS  Google Scholar 

  21. Morrison, R.S. (1991) Suppression of basrc tibroblast growth factor expression by antisense oligodeoxynucleotides inhabits the growth of transformed human astrocytes J Biol Chem 266, 728–734.

    PubMed  CAS  Google Scholar 

  22. Bergan, R, Connell, Y, Fahmy, B, and Neckers, L M (1993) Electroporatron enhances c-myc antrsense ohgodeoxynucleotide efficacy Nucleic Acids Res 21, 3567–3573

    Article  PubMed  CAS  Google Scholar 

  23. McManaway, M E, Neckers, L M, Loke, S L, Al-Nasser, A A, Redner, R L, Shiramizu, B T, Goldschmidts, W L, Huber, B E., Bhatra, K., and Magrath, I T (1990) Tumor-specific inhrbition of lymphoma growth by an antisense ohgodeoxynucleotide. Lancet 335, 808–811.

    Article  PubMed  CAS  Google Scholar 

  24. Goodarzr, G, Watabe, M, and Watabe, K (1992) Organ dtstribution and stabihty of phosphorothioated ollgodeoxynucleotides in mice. Biopharm Drug Dispos 13, 22l–227

    Google Scholar 

  25. Inagakr, M, Togawa, K., Carr, B.I., Ghosh, K., and Cohen, J S (1992) Antrsense oligonucleotides inhibition of liver cell prohferation and in vivo disposition Transplant Proc 24, 2971–2972

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Clinical Pharmacology Branch, National Cancer Institute, Bethesda, MD

    Leonard M. Neckers, Daniel Geselowitz, Christine Chavany, Luke Whitesell & Raymond Bergan

Authors
  1. Leonard M. Neckers
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Daniel Geselowitz
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Christine Chavany
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Luke Whitesell
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Raymond Bergan
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Hybridon, Inc., Worcester, MA

    Sudhir Agrawal

Rights and permissions

Reprints and permissions

Copyright information

© 1996 Humana Press Inc., Totowa, NJ

About this protocol

Cite this protocol

Neckers, L.M., Geselowitz, D., Chavany, C., Whitesell, L., Bergan, R. (1996). Antisense Efficacy. In: Agrawal, S. (eds) Antisense Therapeutics. Methods in Molecular Medicine, vol 1. Humana Press. https://doi.org/10.1385/0-89603-305-8:47

Download citation

  • DOI: https://doi.org/10.1385/0-89603-305-8:47

  • Publisher Name: Humana Press

  • Print ISBN: 978-0-89603-305-4

  • Online ISBN: 978-1-59259-585-3

  • eBook Packages: Springer Protocols

Publish with us

Policies and ethics

Search

Navigation